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Abstract Currently, the most popular form of testosterone
replacement is the topical gels that require daily applications
and incur a risk of transfer of testosterone to partners and
family. One of the problems with testosterone replacement is
the short half-life of testosterone. A long-acting formulation is
appealing to patients and physicians. In 1972, fused crystal-
line testosterone pellets were approved in the USA by the
FDA but they were not marketed until 2008. Pharmacokinet-
ics studies were available on a different formulation from
which much can be learned and applied to the current formu-
lation, Testopel®. The decay kinetics, pituitary suppression,
and effect on other sex steroids are reviewed as well as the
short-term complication rates. This review should provide the
testosterone pellet implanter a better understanding of the
physiology of testosterone pellet supplementation for
hypogonadism.
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Introduction
The benefits of testosterone replacement for the treatment of
hypogonadism are well documented. As men age, there is a
steady decline in testosterone due to an aging pituitary-
gonadal axis. Current treatment modalities require repeated
testosterone injections or topical application of gels. Long-term
topical and injection therapy are fraught with poor long-term
compliance due to the inconvenience of the application and
vacillating serum levels. An ideal therapy would be one that is
easy to administer, provides reliable levels, and is affordable.
Long-lasting testosterone (T) pellets were FDA-approved
in 1972. At that time, the only other options available were
inexpensive generic intramuscular T injections. Testopel®
which was approved by the FDA is crystalline T, formulated
in 75-mg pellets (3×8 mm) with a surface area of 98 mm2.
The pellets are surgically placed in the subcutaneous space
and gradually dissolve. Their long-lasting effect is presumed
to be due to the gradual dissolution of the pellets in the
relatively hypovascular subdermal space [1]. The formulation
lay “dormant” until 2008 when the patent was purchased by a
newly formed company, Slate. The T pellets were named
Testopel®. T replacement therapy evolved between 1972
and 2008. With increased therapeutic formulations, incessant
direct-to-consumer advertising, and the increasing number of
males of the baby boom generation (born circa 1946–1964)
seeking “eternal youth,” T replacement therapy had evolved
into a multibillion-dollar pharmaceutical industry.
Gels Versus Pellets
Gel-based T replacements have since become the preferred
method of therapy since their introduction. The noninvasive
nature of gels made it an appealing alternative to T injections.
Yet, the need for daily applications, erratic absorption, low
long-term compliance rates, the risk of T transfer to family
members, and the expense of the monthly prescriptions
opened the window for a “new” form of T therapy. Testopel®
was thus a welcome new addition to the armamentarium as it
required a simple procedure three to four times a year and
delivered eugonadal T levels for periods from 3 to 6 months.
Day-to-day compliance was not an issue and as such, the
therapeutic efficacy was more easily assessed. Unfortunately,
the prescribing information, a reflection of the regulatory
standards of 1972, was lacking in specific information as to
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the mechanism of dissolution, the recommended dosing, the
insertion technique, the pharmacokinetics, the dosing recom-
mendations, and the data on the dosing frequency. Bioavail-
ability studies were deferred with the original FDA applica-
tion [2]. Information in the package insert was based on
observations and extrapolations from data on injectable T
propionate, a short-acting T ester that is no longer used. It is
unclear whether any pharmacokinetic studies were ever done
on the actual Testopel® pellets. There are certainly no pub-
lished studies prior to 2009 on the currently FDA-approved
Testopel® pellets.
Pellet Pharmacokinetics
Much of the data on T pellet pharmacokinetics comes from
work from Handelsman in Australia. The only peer-reviewed
publications on T pellets are based on a pellet formulation that
has never been approved in the USA produced by Organon.
Nonetheless, much can be learned about the pharmacokinetics
of T pellets by a critical review of those studies. In 1988,
Handelsman conducted a randomized crossover comparator
study in 15 previously treated hypogonadal men (9 primary
and 6 secondary), using the Organon product of T pellets (6×
100 mg). Resulting hormonal levels were the primary end-
points. This formulation is more in line with the currently used
Testopel® pellets in terms of pellet surface area and T dose.
The comparator arms were injectable T esters (250 mg every
2 weeks) and oral Tundecanoate (not available in the USA).
The hormone levels after injectable T were assessed weekly
for 1 month whereas in the T pellets levels were measured
weekly for 1 month then monthly thereafter until the levels
returned to baseline. Levels on the pellets peaked at 781 ng/dl
at 3 weeks and returned to baseline (247 ng/dl) by week 20.
Extrapolating from the data presented in the paper, a level of
300 ng/dl was reached at around 13 weeks. Serum chemistries
and hematologic parameters were unchanged throughout the
study. Both the pellet and injection group reported consistent
subjective improvement in libido, potency, muscular strength,
and general well-being.With equal numbers (six) of pellet and
injection subjects, patients opted to stay on their respective
therapies. Reflecting the early experience with the pellets, 6 of
15 men (40 %) extruded at least one pellet though no wound
infections occurred. Six 100-mg pellets were found to main-
tain T levels for up to 4 months [3].
In 1990, Handelsmen published an open-label crossover
pharmacokinetic study in 43 men (22 hypergonadotropic and
21 hypogonadotropic) on the three regimens (6×100 mg, 6×
200 mg, and 3×200 mg), measuring T levels at monthly
intervals. The treatments were crossed over at 6 months. The
surface areas were 200 and 100 mm2 for the 200- and 100-mg
pellet, respectively. Pellets were inserted into the sub dermal
fat in the lower abdominal wall at the level of the umbilicus.
Each pellet was inserted into its own tract 5–10 cm from the
insertion site. He found that T levels correlated highly with the
dose inserted. The levels in men with 1200 mg were nearly
twice that of the men with a 600-mg insertion. Rates of
absorption of T from the pellets were constant with a “near
linear zero-order release of T over months that was not influ-
enced by the size or number of pellets. The estimated half-
time of absorption was approximately 2.5 months and the rate
of T release was 1.3 mg/day for the 200 mg pellet and
0.65 mg/day for the 100 mg pellet.” Despite a constant ab-
sorption of T from the pellets, serum T levels peaked at
1 month and decreased monthly thereafter, supportive of
first-order decay kinetics. This would suggest that as the
pellets dissolve, the surface area decreases and the amount
of T delivered decreases. Ninety percent of T is metabolized
by hepatic CYP3A4, with approximately 10 and 1 % metab-
olized by 5 alpha reductase and aromatase inhibitor, respec-
tively. As the Km of the CYP3A4 metabolism is 50,000
nanomoles, the metabolism of T is physiologically impossible
to saturate [4]. The kinetics of T decay must therefore be all
attributable to the dissolution of the pellets in the subcutane-
ous space. Based on some intact extruded pellets and assum-
ing that the extruded pellets had comparable dissolution prop-
erties to intact in situ pellets, he extrapolated a dissolution rate
of 1.5 mg/day and maintenance of eugonadal ranges for 4–
5 months. He calculated a therapeutic half-life of 2.5 months.
As production rate of endogenous T is 3–9 mg/day [5], 400–
1200 mg of pellets could produce eugonadal ranges for 4–
6 months. LH levels, measured only in the primary
hypogonadal men only, were markedly and uniformly sup-
pressed for 1–4 months. Their levels inversely mirrored de-
clining T levels. The reproducible effect of the pellets on
gonadotropins was the basis for him recommending using
them to augment clinical monitoring. SHBG levels were not
affected. He reported a 10 % (10/111) extrusion rate. The
frequency of pellet extrusion fell dramatically with increased
experience from an incidence of 40 % after the first 15
procedures to 5 % in the later 96 implants. Some palpable
fibrosis at the insertion site in some men was seen long after
the pellets were dissolved. Seventy percent (30/43) expressed
a desire to continue with the pellets versus injections [6].
In 1996, Jockenhovel published a comprehensive pharma-
cokinetic study in 14 profoundly hypogonadal men (baseline
T of 34 ng/dl) using the 6×200 mg formulation. Only three of
the men had idiopathic secondary hypogonadism. Measuring
T levels nine times in the first 48 h, a burst release of T was
seen with a Cmax of 144 ng/dl. T levels stabilized for 63 days
following which first order decay occurred. Estradiol levels
peaked at 42 days, at 38 pgm/ml. At 180 days, the mean serum
T was 300. Both LH and FSH exponentially decreased after
insertion, inversely mirroring Tand estradiol levels. An inter-
esting observation was the volume of distribution increased
while T1/2 decreased with increasing BMI. Their mean BMI
was less than 25.kg/m2. This observation is not surprising as T
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in the periphery equilibrates quickly between most organs and
the blood [7]. Men with larger BMIs have, in general, a larger
volume of distribution. When considering pellets in obese
patients, they might need significantly more pellets. Despite
a 5 % extrusion rate, all but one of the men expressed the
desire to continue with the pellets [8].
Complications, Insertion Technique, and Dosing
In a retrospective survey, Handelsman determined that extru-
sions were increased by early post implantation increased
physical activity [9]. Experiencing an incidence of extrusions
(5–12 %) and infections (1.4–6.8 %), he set about to deter-
mine if complication rates were affected by the technique, site
of insertion, washing of the pellets, impregnation of the pellets
with antibiotics, and experience of the implanter. Using the
anterior abdominal wall insertion technique, he found that
none of the aforementioned variables influenced extrusion or
infection rates. Whereas extrusions associated with infections
usually occur at a median of 4 weeks, extrusions without
apparent infections occurred at 9 weeks [10, 11].
In 2004, Handelsman reviewed his experience in 136 men
with a standard dose of 800 mg (4×200 mg pellets). Pellets
were placed under the skin of the lateral abdominal wall or the
lateral aspects of the buttocks along the pants line. Re-
implantations were based on symptoms alone without any
reminders to the patients. His extrusion rate was approximate-
ly 10 %. T levels were drawn at the implantation visit (median
299 vs baseline of 144). If extrusions occurred, the men were
instructed to keep the pellets and make a note of the day of the
extrusion. The pellets were desiccated upon return to the clinic
and weighed to determine the amount that was left. No quan-
titative measurement was made of the remaining T in the
pellet. A linear regression curve was generated by the desic-
cated weight and the day of extrusion, and a pellet dissolution
rate of 1.31 mg/day was calculated. Only intact pellets were
used and the pellets maintained their cylindrical shape for a
median of 98 days. As nadir levels were unpredictably
lowered by increased number of extrusions, one might ques-
tion the strength of his assumptions. Is an extruded pellet
biologically equivalent to one in situ? Handelsman suggested
that a dose four pellets of 200 mg should last 5.8 months. The
questions remain as to the relevance of these observations to
the current Testopel® preparation. Are the formulations truly
bioequivalent? Does pellet fragmentation occur during inser-
tion? Are the decay curves the same? How does BMI affect
the peak serum levels and decay curve? Should symptoms or
T levels be used as replacement criteria?
Studies and Clinical Experience
The literature on Testopel® implantation was nonexistent until
the 2008 introduction of the product in the US market. In
2009, Cavender et al. published a single-site retrospective
review of his experience with the 75-mg Testopel® pellets in
80 men (272 insertions) treated for clinical hypogonadism
(T<350 ng/dl). The series was uncontrolled and retrospec-
tive and with variable follow-up and treatments. It was not
intended as a pharmacokinetic study but a report of a clinical
experience and represented the first published reported clini-
cal experience with Testopel®. Dosing of the pellets was
arbitrarily based on severity of symptoms, body weight, age,
and lifetstyle. The insertion technique was a modification of
the Handelsmen lateral jackknife position and utilizeda pro-
prietary trocar. Reported infection rates and extrusion rates
were considerably lower than Handelsman at 0.3 and 0.3 %
respectively, reflecting the different formulation, technique,
experience of implanter, patient selection, or a combination of
all the factors. Although he demonstrated normalization of T
levels, because of the variability of the patients, treatments,
and inclusion criteria, little could be concluded from the paper
other than Testopel® could be expected to produce results at
least similar tothe Organon product and that it appeared to be
at least as well tolerated[12•].
Kaminetsky published an industry-supported, FDA-ap-
proved, pharmacokinetic study in 30 men with Testopel®
[13••]. Dosing was based on BMI and baseline T levels and
the insertion technique that was published by Cavender.
Twenty-eight men received treatment (8 pellets, n=3; 10
pellets, n=14; 12 pellets, n=12). None met the criteria for
six pellets (baseline T of <315 ng/dl and a BMI of <18). Peak
T levels at 1 month were dose dependent with 100, 100, 86,
75, and 14 % above 315 ng/dl at weeks 1, 4, 12, 20, and 24,
respectively. The continuation phase of the study in (22 of 28
men) revealed that 100 and 31.8 had levels >315 ng/dl at week
4 and 16 after treatment. This would suggest that biologic
variability of treatment effect might be expected from one
treatment to the next for unexplained reasons. Previous studies
have not investigated the reproducibility of the levels from
one insertion to the next. During phase 1 of the study, erectile
function scores increased clinically significantly in the first
12 weeks of treatment though the score returned to baseline at
the end of the study. Though clinically significant, there was
no placebo arm. As in other studies, pituitary gonadotropins
were suppressed as Tand estradiol levels increased. Unlike the
Handelsman experience, no extrusions or infections were
reported.
The findings in the Kaminetsky study though reassuring
about the safety and efficacy of the Testopel® was in stark
contrast to the FDA-approved 1972 package insert provided
with the product, recommending 150–450 mg (two to six
pellets) every 3–6 months. None of the studies thus reported
results with such low dosing. In an attempt to provide some
clarity McCullough et al. published an independent multi-
institutional study on 380 patients with 702 insertions at 6
institutions. This represented the early experience at each
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institution. Investigators pooled their data on pre-insertion and
post-insertion T levels along with the number of implanted
pellets. The number of pellets to be inserted and the tech-
niques used were based on the clinical experience of each
investigator though all but one started with six pellets. Unlike
the Kaminetsky study, pre-treatment level of T or BMI were
not used as a criteria for the number of pellets required. With
multiple investigators using their own criteria for treatment
and follow-up, this represented a more generalizable guide for
the new implanter. Though the T levels at 4 weeks were
comparable for all pellet levels, patient and investigator disen-
chantment with subsequent levels lead investigators to insert
more than the minimum number of pellets. Six or seven pellets
were utilized in only 10 % of the insertions with 10 or more
pellets being inserted in 63 %. The insertion of 10 or more
pellets resulted in eugonadal levels for a longer period of time.
Regardless of the number inserted, all men were hypogonadal
at 6 months with most men requiring re-implantation after
4 months, much like the 1988 Handelsman study with the
Organon 100-mg pellets. T levels appeared to decay exponen-
tially behaving like first-order decay kinetics. Unlike in the
Handelsman study with 200-mg pellets, inserting more pellets
did not increase the period of time between insertions consis-
tent with an exponential decay [14••].
In 2012, Pastuszak et al. reported their follow-up of 273
men, many of whom were in the original multi-institutional
study. The indications for treatment were clinical
hypogonadism. Mean initial T level was 328 (208)ng/dl and
BMI 30 (5). Sixty-eight men had been diagnosed with prostate
cancer. Based on observed levels determined at various time
points, decay curves were calculated. Unlike the Jockenhovel
pharmacokinetic study, many of the conclusions drawn were
from extrapolated data and not from actual measured levels.
This retrospective observational study examined the effect of
initial T level, BMI, multiple insertions, and the number of
pellets inserted. Like the multi-institutional study, adequate
numbers in the 6–7-pellet group were lacking. Ninety-five
percent of the men were treated with 10 or more pellets. The
authors found that early post-insertion T levels were impacted
by the number of pellets inserted. Higher levels were achieved
with more pellets. As endogenous T production is virtually
shut down with exogenous replacement, the initial T level did
not impact subsequent T levels. There is therefore no need to
titrate the number of pellets based on the initial T level as was
done in the Kaminetsky pharmacokinetic trial. Men with
BMIs less than 25 achieved higher levels than those with a
BMI greater than 25, and the decay is faster. This supports the
concept that volume of distribution affects subsequent hor-
mone levels, as demonstrated by Jockhovel. Regardless of the
number of insertions, number of pellets implanted, initial T
level, or BMI, most men needed re-implantation between 3
and 4 months after the insertion. No men experienced a
significant increase in the hematocrit or hemoglobin and no
men with documented prostate cancer experienced progres-
sion for their disease. No men developed prostate cancer
during the period of observation. Extrusion and infection rate
were 1.1 and 0.4 % respectively, suggesting inherent differ-
ences in the nature of the pellets [15••].
Patient Experience and Satisfaction
There have been several single-center papers addressing treat-
ment satisfaction and compliance with Testopel®. Khera et al.
investigated a small series of young men (4) with Klinefelters
who would be requiring lifetime T replacement. Compliance
with the Testopel® formulation was better than gels or injec-
tions [16]. Liphultz looked at patient satisfaction rates at
Baylor via a survey based on patient recall. The choice of
therapy was heavily influenced by physician recommendation
with 53, 31, and 17 % choosing injections, gels, and
Testopel®, respectively. Overall, approximately 70 % of pa-
tients were satisfied with their respective treatments regardless
of modality used. Though the pellets were favored because of
the ease and convenience of use, injections were favored
because of their decreased cost [17•]. Regional differences in
insurance reimbursement can clearly impact patient prefer-
ences. Placebo-controlled studies on patient reported out-
comes are understandably lacking with Testopel®.
As with type 2 diabetes, barring major lifestyle changes,
hypogonadism is a lifetime problem for which men need
treatment. Clearly, T pellets offer some advantages with re-
spect to the maintenance of consistent eugonadal levels of T.
There are unfortunately no long-term studies of the use of T
pellets. As with any surgical procedure, with repeated inser-
tions, the cumulative risk of an extrusion, hematoma, or infec-
tion increases. Anecdotally, many implanters have found that
with repeated insertions, subcutaneous fibrosis occurs, making
the insertions more difficult. In an effort to increase the interval
between insertions, McCullough et al. combined anastrozole,
an aromatase inhibitor with Testopel®. The theory was that if
the metabolism of Testopel® could be slowed down, T levels
might remain eugonadal for a longer period of time and the
interval between insertions increased. Thirty-eight men with
65 insertions were analyzed. T levels at up at 120 days were
comparable between the groups. With the addition of
anastrozole, T levels were maintained at eugonadal levels for
over 120 days. Mean re-insertion time was increased from 124
(22) to 194 (62)days. Twenty-five percent did not require a re-
insertion. The mechanism though had nothing to do with a
decrease in T metabolism but was secondary to the inhibition
of the suppressive effect of T replacement on pituitary gonad-
otropins and endogenous production. Men on Testopel® and
anastrozole did not demonstrate the secondary increase in their
estradiol levels or suppression of their LH and FSH levels. The
addition of a generic aromatase inhibitor significantly de-
creased the number of annual Testopel® insertions [18•].
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Conclusions
The use of T implants as a form of T replacement has been
reported since 1938 [19]. The formulation approved by the
FDA in 1972 was Testopel®. Despite a lack of information
provided by the package insert, there is a wealth of information
available through peer-reviewed studies on similar prepara-
tions and the product itself. Pellets provide sustained eugonadal
T levels for 3–6months. Contemporary studies suggest that the
FDA recommended 3–6 pellets are inadequate for most men
and that 10 pellets (750 mg) produce the most reliable levels.
Post implantation levels are affected by the volume of distri-
bution, i.e., thin men require fewer, whereas morbidly obese
men might require more. Extrusion and implantation infection
rates at high-volume centers with Testopel® are less than 1 %,
and patient acceptance of the procedure is very high. As with
all forms of replacement therapy, close monitoring of thera-
peutic efficacy is important. More long-term studies on clinical
efficacy and safety are needed.
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